Skip to main content
. Author manuscript; available in PMC: 2019 Apr 22.
Published in final edited form as: Mol Imaging Biol. 2017 Jun;19(3):421–428. doi: 10.1007/s11307-016-1008-z

Fig. 3.

Fig. 3.

4-[18F]F-Gln uptake is not affected by BRAF-targeted therapy in wild-type BRAF, HCT-116 colon cancer xenografts. Representative transverse and coronal a 4-[18F]F-Gln and b [18F]FDG PET images of HCT-116 xenograft tumor-bearing vehicle or BEZ-235/PLX-4720-treated mice; tumors are denoted by white arrows. PET quantification of tissue %ID/g revealed no significant difference between vehicle and any of the treated cohorts for c 4-[18F]F-Gln while d [18F]FDG PET was significantly reduced non-selectively in all the treated cohorts. e As expected, PLX-4720 exposure did not result in any difference in pERK levels in HCT-116 xenografts while single-agent BEZ-235 and BEZ-235/PLX-4720 combination treatment led to decreased pAKT. f Changes in HCT-116 tumor volume by the tenth day of treatment (N ≥ 8 for all cohorts), shown as percent change from day 1 baseline, revealed no significant reduction in size from vehicle-treated mice for any of the treated tumors.